DNA Repair Deficiencies and the Promise of PARP Inhibition in Prostate Cancer: Clinical Implications

Urology Sympo 2018
In this on-demand Webcast of a CCO symposium at AUA 2018 for the practicing urologist, CCO’s expert faculty explore PARP inhibitor therapy in prostate cancer, including a review of the latest data on DNA repair deficiencies, insights into practical challenges associated with genetic testing for DNA repair defects, and a review of available clinical data on PARP inhibitors and how these agents may affect management strategies for patients in the near future.
Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD
Program Director
William B. Isaacs, PhD
Todd M. Morgan, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 22, 2018 Expiration: June 21, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or ATM mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents or therapies in prostate cancer

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD

Professor of Experimental Cancer Medicine
Department of Medicine and Drug Development
Institute of Cancer Research
Honorary Consultant Medical Oncology
Department of Medicine and Drug Development
Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, United Kingdom

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, has disclosed that he has received consulting fees from AstraZeneca, Genentech, GlaxoSmithKline, Merck Serono, and MSD.


William B. Isaacs, PhD

Department of Urology
Johns Hopkins School of Medicine
Baltimore, Maryland

William B. Isaacs, PhD, has no real or apparent conflicts of interest to report.
Todd M. Morgan, MD

Associate Professor
Department of Urology
University of Michigan
Ann Arbor, Michigan

Todd M. Morgan, MD, has disclosed that he has received consulting fees from Myriad Genetics and funds for research support for GenomeDx, MDxHealth, and Myriad Genetics.


Rachael M. Andrie, PhD

Associate Scientific Director

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for urologists and other healthcare providers who care for patients with prostate cancer.


The goal of this activity is to improve participants’ knowledge of BRCA and other DNA repair gene testing as well as competence in applying the latest data on PARP inhibitors to optimize the treatment of patients with prostate cancer.

Physician Continuing Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 22, 2018, through June 21, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Phase III TITAN trial of apalutamide + ADT for patients with metastatic castration-sensitive prostate cancer, as reported by CCO from ASCO 2019.

Released: June 7, 2019

Results from the phase III ENZAMET trial of enzalutamide in metastatic hormone-sensitive prostate cancer as reported by CCO from ASCO 2019

Released: June 6, 2019

Download this free slideset by Todd M. Bauer, MD, for a brief overview of the optimal treatment options for patients with NTRK, ROS1, FGFR, or RET altered tumors.

Todd M. Bauer, MD Released: June 3, 2019

Updated data showing that darolutamide plus ADT delays disease-related symptoms and maintains QoL in nonmetastatic CRPC reported by CCO from ASCO 2019.

Released: June 2, 2019
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

This activity is supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?